Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

GI pharm > Tumors of GI system > Flashcards

Tumors of GI system Flashcards

1
Q

Drugs used for anal cancer

A

cisplatin, mitomycin, 5FU

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Drugs used for CRC

A

bevacizumab, capecitabine, cetuximab, 5FU

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Drugs used for esophageal cancer

A

Cisplatin, Docetaxel, 5FU

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Drugs used for gastric cancer

A

cisplatin, docetaxel, 5FU, trastuzumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Drugs used for GI carcinoid

A

octreotide, interferon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Drugs used for GIST

A

imatinib, sunitinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Drugs used for pancreatic cancer

A

5FU, erlotinib, gemcitabine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Drugs used for liver cancer

A

5FU

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is 1st/2nd line therapy for esophageal cancer?

A

Cisplatin + 5FU. docetaxel is 2nd line

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How should you determine gastic cancer therapy

A

Check Her2 status. If positive, trastuzumab should be added to 5FU/cisplatin therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How do you determine CRC therapy?

A

Capecitbine or 5FU + bevacizumab or cetuximab unless KRAS +

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What drug is associated with tachyphylaxis?

A

octreotide- duration of treatment is 12 months usually

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Treatment with conventional chemo is GIST is futile due to ____.

A

overexpression of P-gp

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

GIST can be categorized into what groups?

A

KIT-mutant (80%), KIT negative, PDGFRA-mutant, wild-type

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

MOA bevacizumab

A

rhuMAab-VEGF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Bevacizumab issues

A

bleeding, perforation, wound dehisence, HTN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Capecitabine MOA

A

5FU prodrug

18
Q

Capecitabine issues

A

DPD deficiency prevents metabolic activation. CI in renal dysfunction. Adverse CV events. Neuro and heme toxicities

19
Q

Cetuximab MOA

A

EGFR Ab

20
Q

Cetuximab issues

A

Cardiac arrest, respiratory arrest, sudden death, acneiform, infusion rxn

21
Q

Cisplatin MOA

A

DNA crosslinks and adducts

22
Q

Cisplatin issues

A

ototoxicity, NEPHROTOXICITY, BMS

23
Q

Docetaxel MOA

A

Stabilize microtubule

24
Q

Docetaxel issues

A

Increased tx related morality in NSCLC; edema, neuropathy, CI in hepatic disease, DLT: neutropenia

25
Q

Erlotinib MOA

A

EGFR-TKI

26
Q

Erlotinib issues

A

GI tox, bleeding, LFTs, ocular toxicities, rarely ILD

27
Q

5FU MOA

A

pyrimidine antimetabolite that inhibits TS and interferes with RNA synthesis and effects DNA

28
Q

5Fu issues

A

DPD deficiency = enhanced neurotoxicity, severe heme tox and BMS

29
Q

Gemcitabine MOA

A

DNA polymerase inhibitor, incorporates triphosphate

30
Q

Gemcitabine issues

A

BMS, infection, sensory peripheral neuropathy, arthralagia, drowsiness, anorexia resolves in 2-3 days

31
Q

imatinib MOA

A

TKI adjuvant with resection of KIT mutant GIST

32
Q

Imatinib issues

A

GI tox, CHF, neuro tox, fluid retention, edema

33
Q

Inf-a MOA

A

enzyme activation following cell surface receptor binding and TK activation

34
Q

inf-a issues

A

neuropsychiatric events, FLS

35
Q

Mitomycin MOA

A

alkylating agent

36
Q

Mitomycin issues

A

BMS, thrombocytopenia, leukopenia, HUS

37
Q

Octreotide MOA

A

SS, reduce duodenal bicarb, amylase, gastric acidity, gallbladder contractility, bile secretion, inhibits meal induced increases in SMA and portal venous blood flow

38
Q

Octreotide issues

A

monitor blood glucose, dose-related diarrhea

39
Q

Sunitinib MOA

A

inhibitor of >80 RTKs

40
Q

Sunitinib issues

A

Thrombocytopenia, bleeding, QT prolongation, GI complications including perforation

41
Q

Trastuzumab MOA

A

HER2-neu antibody. Inhibition of Her2–> accumulation of cdk inhibitor p26–> cell cycle arrest. Inhibits constitutive Her2 shedding by MP (correlate with clinical activity)

42
Q

Trastuzumab issues

A

LVEF dysfunction, cardiomyopathy, anaphylaxis, angioedema, pulmonary toxicity

GI pharm (7 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions